Autolus Therapeutics (NASDAQ:AUTL) just reported results for the second quarter of 2024.
- Autolus Therapeutics reported earnings per share of -22 cents. This was below the analyst estimate for EPS of -19 cents.
- The company did not report any revenue for the quarter.